Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer
Yoshikane Nonagase(Kindai University), Kazuhiko Nakagawa(Dana-Farber Cancer Institute)
Cited by 13
Related Papers
Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer
|Clinical Cancer Research|2011|141
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
|British Journal of Cancer|2011|120
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
|British Journal of Cancer|2008|101
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
|Clinical Cancer Research|2021|92
[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification
|International Journal of Cancer|2019|90